| n = 86 . | ||
|---|---|---|
| Clinical | Age*, years | 60 [35–76] |
| Male, n | 49 (57.0%) | |
| MGMT methylated, n | 41 (47.7%) | |
| Molecular GBM | 5 (5.8%) | |
| Time from diagnosis to scan, months | 9.6 [3.9–71.2] | |
| Follow-up from scan, months | 11.4 [0.8–71.3] | |
| Prior surgery | Time from last surgery*, months | 6.6 [0.5–71.2] |
| Biopsy only, n | 10 (11.6%) | |
| Radiotherapy | 30 F × 2 Gy with concomitant TMZ, n | 74 (86.1%) |
| 30 F × 2 Gy (no TMZ), n | 4 (4.7%) | |
| 10 F × 3.4 Gy, n | 5 (5.8%) | |
| 33 F × 1.8 Gy, n | 1 (1.1%) | |
| No RT, n | 2 (2.3%) | |
| Time from end of radiotherapy*, months | 7.5 [1.8–67.2] | |
| Adjuvant TMZ* | Number of series, n [range] | 5 [0–11] |
| No adj. TMZ, n | 8 (9.2%) | |
| Steroid use* | Yes, n | 30 (35.3%) |
| WHO performance status* | 0–1, n | 56 (65.1%) |
| 1–2, n | 4 (4.6%) | |
| ≥2, n | 18 (20.9%) | |
| n.a., n | 8 (9.3) | |
| Location, n | Frontal | 22 (25.6) |
| Parietal | 13 (15.1) | |
| Temporal | 20 (23.3) | |
| Occipital | 8 (9.3) | |
| Striatum/thalamus | 2 (2.3) | |
| Cerebellum | 1 (1.2) | |
| >1 lobe** | 20 (23.3) |
| n = 86 . | ||
|---|---|---|
| Clinical | Age*, years | 60 [35–76] |
| Male, n | 49 (57.0%) | |
| MGMT methylated, n | 41 (47.7%) | |
| Molecular GBM | 5 (5.8%) | |
| Time from diagnosis to scan, months | 9.6 [3.9–71.2] | |
| Follow-up from scan, months | 11.4 [0.8–71.3] | |
| Prior surgery | Time from last surgery*, months | 6.6 [0.5–71.2] |
| Biopsy only, n | 10 (11.6%) | |
| Radiotherapy | 30 F × 2 Gy with concomitant TMZ, n | 74 (86.1%) |
| 30 F × 2 Gy (no TMZ), n | 4 (4.7%) | |
| 10 F × 3.4 Gy, n | 5 (5.8%) | |
| 33 F × 1.8 Gy, n | 1 (1.1%) | |
| No RT, n | 2 (2.3%) | |
| Time from end of radiotherapy*, months | 7.5 [1.8–67.2] | |
| Adjuvant TMZ* | Number of series, n [range] | 5 [0–11] |
| No adj. TMZ, n | 8 (9.2%) | |
| Steroid use* | Yes, n | 30 (35.3%) |
| WHO performance status* | 0–1, n | 56 (65.1%) |
| 1–2, n | 4 (4.6%) | |
| ≥2, n | 18 (20.9%) | |
| n.a., n | 8 (9.3) | |
| Location, n | Frontal | 22 (25.6) |
| Parietal | 13 (15.1) | |
| Temporal | 20 (23.3) | |
| Occipital | 8 (9.3) | |
| Striatum/thalamus | 2 (2.3) | |
| Cerebellum | 1 (1.2) | |
| >1 lobe** | 20 (23.3) |
Abbreviations: TMZ = temozolomide, Gy = Gray, F = fractions, n = number of patients.
All value are n (%) or median [range].
*at time of scan.
**involvement of more than a single lobe, region, or hemispheres
| n = 86 . | ||
|---|---|---|
| Clinical | Age*, years | 60 [35–76] |
| Male, n | 49 (57.0%) | |
| MGMT methylated, n | 41 (47.7%) | |
| Molecular GBM | 5 (5.8%) | |
| Time from diagnosis to scan, months | 9.6 [3.9–71.2] | |
| Follow-up from scan, months | 11.4 [0.8–71.3] | |
| Prior surgery | Time from last surgery*, months | 6.6 [0.5–71.2] |
| Biopsy only, n | 10 (11.6%) | |
| Radiotherapy | 30 F × 2 Gy with concomitant TMZ, n | 74 (86.1%) |
| 30 F × 2 Gy (no TMZ), n | 4 (4.7%) | |
| 10 F × 3.4 Gy, n | 5 (5.8%) | |
| 33 F × 1.8 Gy, n | 1 (1.1%) | |
| No RT, n | 2 (2.3%) | |
| Time from end of radiotherapy*, months | 7.5 [1.8–67.2] | |
| Adjuvant TMZ* | Number of series, n [range] | 5 [0–11] |
| No adj. TMZ, n | 8 (9.2%) | |
| Steroid use* | Yes, n | 30 (35.3%) |
| WHO performance status* | 0–1, n | 56 (65.1%) |
| 1–2, n | 4 (4.6%) | |
| ≥2, n | 18 (20.9%) | |
| n.a., n | 8 (9.3) | |
| Location, n | Frontal | 22 (25.6) |
| Parietal | 13 (15.1) | |
| Temporal | 20 (23.3) | |
| Occipital | 8 (9.3) | |
| Striatum/thalamus | 2 (2.3) | |
| Cerebellum | 1 (1.2) | |
| >1 lobe** | 20 (23.3) |
| n = 86 . | ||
|---|---|---|
| Clinical | Age*, years | 60 [35–76] |
| Male, n | 49 (57.0%) | |
| MGMT methylated, n | 41 (47.7%) | |
| Molecular GBM | 5 (5.8%) | |
| Time from diagnosis to scan, months | 9.6 [3.9–71.2] | |
| Follow-up from scan, months | 11.4 [0.8–71.3] | |
| Prior surgery | Time from last surgery*, months | 6.6 [0.5–71.2] |
| Biopsy only, n | 10 (11.6%) | |
| Radiotherapy | 30 F × 2 Gy with concomitant TMZ, n | 74 (86.1%) |
| 30 F × 2 Gy (no TMZ), n | 4 (4.7%) | |
| 10 F × 3.4 Gy, n | 5 (5.8%) | |
| 33 F × 1.8 Gy, n | 1 (1.1%) | |
| No RT, n | 2 (2.3%) | |
| Time from end of radiotherapy*, months | 7.5 [1.8–67.2] | |
| Adjuvant TMZ* | Number of series, n [range] | 5 [0–11] |
| No adj. TMZ, n | 8 (9.2%) | |
| Steroid use* | Yes, n | 30 (35.3%) |
| WHO performance status* | 0–1, n | 56 (65.1%) |
| 1–2, n | 4 (4.6%) | |
| ≥2, n | 18 (20.9%) | |
| n.a., n | 8 (9.3) | |
| Location, n | Frontal | 22 (25.6) |
| Parietal | 13 (15.1) | |
| Temporal | 20 (23.3) | |
| Occipital | 8 (9.3) | |
| Striatum/thalamus | 2 (2.3) | |
| Cerebellum | 1 (1.2) | |
| >1 lobe** | 20 (23.3) |
Abbreviations: TMZ = temozolomide, Gy = Gray, F = fractions, n = number of patients.
All value are n (%) or median [range].
*at time of scan.
**involvement of more than a single lobe, region, or hemispheres
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
